MIPS # PIMSH 16 Appropriate Antiemetic Therapy for High- and Moderate-Emetic-Risk Antineoplastic Agents in the Infusion Center
Measure Description
Percentage of cancer patients aged 18 years and older treated with high- or moderate-emetic-risk antineoplastic agents in the infusion center who are administered appropriate pre-treatment antiemetic therapy
Relevance to Value Based Care
Chemotherapy-induced nausea and vomiting may discourage patients from completing a chemotherapy regimen, adversely impacts quality of life and a patient’s ability to carry out daily activities, and may require emergency care or hospitalization, adding to the economic burden of healthcare (Aapro et al., 2012).
Numerator
Numerator Criteria 1: Patients who are administered prior to treatment a four-drug combination of a neurokinin 1 (NK1) receptor antagonist, a serotonin (5-HT3) receptor antagonist, dexamethasone, and olanzapine
Numerator Criteria 2: Patients who are administered prior to treatment a two-drug combination of a 5-HT3 receptor antagonist, and dexamethasone
Numerator Guidance: For the purposes of the measure, the following antiemetics would meet the measure:
Antiemetics administered on the same day as cycle 1 day 1 of the therapy OR
Any new or refill prescription order of antiemetics on the same day as cycle 1 day 1 of the therapy or within 89 days prior to cycle 1 day 1 of the therapy OR
Any record of antiemetics as active on the medication list within 90 days prior to cycle 1 day 1 of the therapy
Denominator
Denominator Exception Criteria 1: Patient allergy or intolerance to neurokinin 1 (NK1) receptor antagonist, serotonin (5-HT3) receptor antagonist, dexamethasone, or olanzapine
Denominator Exception Criteria 2: Patient allergy or intolerance to 5-HT3 receptor antagonist, or dexamethasone
Exclusion/Exceptions
Denominator Exception Criteria 1: Patient allergy or intolerance to neurokinin 1 (NK1) receptor antagonist, serotonin (5-HT3) receptor antagonist, dexamethasone, or olanzapine
Denominator Exception Criteria 2: Patient allergy or intolerance to 5-HT3 receptor antagonist, or dexamethasone
Scoring
5 points, unless same year benchmark established then 5-10 points.
RESOURCES